Biological evaluation of 2-aryl-2-fluoropropionic acids as possible platforms for new medicinal agents

Chemical and Pharmaceutical Bulletin

Volumn 53, Issue 8, 2005, Pages 1062-1064

  Takeuchi, Yoshio ^a   Fujisawa, Hidehito ^a   Fujiwara, Tomoya ^a   Matsuura, Mamoru ^b   Komatsu, Hirotsugu ^b   Ueno, Satoshi ^c   Matsuzaki, Takeshi ^c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

2 aryl 2 fluoropropionic acid; Chiral fluorinated structure; Epimerization; Non steroidal anti inflammatory drug

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLUOROBUPROFEN; FLUOROFENOPROFEN; FLUOROFLURBIPROFEN; FLUOROKETOPROFEN; FLUORONAPROXEN; HERBACEOUS AGENT; INDOMETACIN; IRINOTECAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESEARCH; DRUG SCREENING; ENANTIOMER; ENZYME INHIBITION; ENZYME MODIFICATION; EPIMERIZATION; FLUORINATION; HUMAN; HUMAN CELL; RACEMIZATION; STRUCTURE ACTIVITY RELATION;

EID: 24944527846     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.53.1062     Document Type: Article

References (14)

1. Ojima I., McCarthy J. R., Welch J. T., "Biomedical Frontiers of Fluorine Chemistry," ACS Symposium Series 639, American Chemical Society, Washington, DC, 1996.
2. Fujisawa H., Fujiwara T., Takeuchi Y., Omata K., Chem. Pharm. Bull., 53, 524-528 (2005).
3. McCracken J. D., Wechter W. J., Liu Y., Chase R. L., Kantoci D., Murray E. D., Jr., Quiggle D. D., Mineyama Y., J. Clin. Pharmacol., 36, 540-545 (1996).
4. Howe L. R., Dannenberg A. J., Semin. Oncol., 29 (Suppl. 11), 111-119 (2002).
5. Khwaja F., Allen J., Andrews P., Djakiew D., Cancer Res., 64, 6207-6213 (2004).
6. Takeuchi Y., Shiragami T., Kimura K., Suzuki E., Shibata N., Org. Lett., 1, 1571-1573 (1999).
7. Man H.-W., Corral L. G., Stirling D. I., Muller G. W., Bioorg. Med. Chem. Lett., 13, 3415-3417 (2003).
8. Chem. Abstr., 136, 247496v (2002), PCT Int. Appl. WO 2002020482.
9. Nakazato A., Kumagai T., Sakagami K., Yoshikawa R., Suzuki Y., Chaki S., Ito H., Taguchi T., Nakanishi S., Okuyama S., J. Med. Chem., 43, 4893-4909 (2000).
10. Hutt A. J., Caldwell J., J. Pharm. Pharmacol., 35, 693-704 (1983).
11. Fournel S., Caldwell J., Biochem. Pharmacol., 35, 4153-4159 (1986).
12. Caldwell J., Hutt A. J., Fournel-Gigleux S., Biochem. Pharmacol., 37, 105-114 (1988).
13. Rhys-Williams W., McCarthy F., Backer J., Hung Y.-F., Thomason M. J., Lloyd A. W., Hanlon G. W., Enzyme Microb. Technol., 22, 281-287 (1998).
14. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K., Cancer Res., 51, 4187-4191 (1991).